7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 
      
    		                            
      net revenue
    		784,513,000 695,420,000 730,518,000 702,468,000 701,780,000 659,191,000  599,046,000 557,540,000 609,759,000 545,557,000 559,355,000 497,633,000 536,896,000 528,593,000 535,075,000 493,105,000 510,034,000 519,294,000 464,662,000 498,533,000 397,328,000 378,283,000 404,642,000 446,120,000 497,528,000 476,487,000 413,787,000 
      cost of goods sold
    		510,539,000 439,529,000 467,645,000 432,910,000 451,833,000 421,131,000  379,025,000 379,354,000 389,046,000 350,653,000 353,724,000 323,062,000 348,490,000 329,394,000 322,577,000 301,543,000 342,962,000 353,345,000 319,666,000 313,578,000 273,373,000 267,717,000 296,381,000 309,743,000 304,120,000 276,382,000 235,492,000 
      gross profit
    		273,974,000 255,891,000 262,873,000 269,558,000 249,947,000 238,060,000  220,021,000 178,186,000 215,388,000 194,230,000 200,519,000 174,571,000 166,402,000 198,511,000 212,498,000 191,562,000 167,072,000 133,585,000 144,237,000 183,499,000 110,234,000 54,434,000 105,249,000 83,080,000 193,408,000 200,105,000 178,295,000 
      yoy
    		9.61% 7.49%  22.51% 40.27% 10.53%  9.73% 2.07% 29.44% -2.16% -5.64% -8.87% -0.40% 48.60% 47.33% 4.39% 51.56% 145.41% 37.04% 120.87% -43.00% -72.80% -40.97%     
      qoq
    		7.07% -2.66% -2.48% 7.85% 4.99%   23.48% -17.27% 10.89% -3.14% 14.86% 4.91% -16.17% -6.58% 10.93% 14.66% 25.07% -7.39% -21.40% 66.46% 102.51% -48.28% 26.68% -57.04% -3.35% 12.23%  
      gross margin %
    		                            
      selling, general and administrative
    		137,815,000 118,288,000 128,687,000 118,692,000 116,462,000 112,595,000  105,570,000 102,096,000 102,158,000 100,071,000 98,806,000 98,665,000 97,224,000 91,397,000 86,157,000 90,726,000 84,687,000 83,120,000 80,944,000 77,976,000 74,084,000 63,797,000 67,281,000 84,436,000 74,236,000 78,075,000 53,003,000 
      research and development
    		63,352,000 40,040,000 54,265,000 61,097,000 36,054,000 39,298,000  37,799,000 38,690,000 41,907,000 50,235,000 50,748,000 52,798,000 51,874,000 48,927,000 52,864,000 48,182,000 53,460,000 44,519,000 45,572,000 36,379,000 48,050,000 38,125,000 48,016,000 53,858,000 56,647,000 42,999,000 50,335,000 
      intellectual property legal development expenses
    		2,437,000 1,767,000 1,852,000 1,967,000 1,042,000 984,000  820,000 1,644,000 1,362,000 1,411,000 821,000 764,000 1,142,000 1,627,000 1,365,000 3,582,000 3,701,000 2,134,000 3,550,000 1,270,000 4,975,000 2,586,000 2,511,000 4,166,000 3,237,000 4,401,000 4,047,000 
      restructuring and other charges
    		143,000 571,000 493,000 172,000 220,000 1,470,000  82,000 510,000 109,000 581,000  731,000 1,069,000 425,000  363,000 -259,000 276,000 333,000 2,048,000 4,412,000 20,937,000 2,835,000 6,161,000    
      (credit) charges related to legal matters
    		  23,727,250 -149,000                         
      other operating income
    		-117,000 -5,122,000      13,000 -1,224,000 -1,465,000 -1,320,000 -1,175,000                 
      operating income
    		70,344,000 100,347,000 75,793,000 88,809,000 95,470,000 -10,746,000  80,084,000 34,449,000 36,032,000 44,353,000 -198,618,000 23,305,000 11,175,000 28,515,000 67,119,000 45,907,000 20,178,000 2,435,000 10,751,000 57,791,000 -23,135,000 -112,274,000 -18,913,000 -94,360,000 23,280,000 74,555,000 -181,062,000 
      yoy
    		-26.32% -1033.81%  10.89% 177.13% -129.82%  -140.32% 47.82% 222.43% 55.54% -395.92% -49.23% -44.62% 1071.05% 524.30% -20.56% -187.22% -102.17% -156.84% -161.25% -199.38% -250.59% -89.55%     
      qoq
    		-29.90% 32.40% -14.66% -6.98% -988.42%   132.47% -4.39% -18.76% -122.33% -952.25% 108.55% -60.81% -57.52% 46.21% 127.51% 728.67% -77.35% -81.40% -349.80% -79.39% 493.63% -79.96% -505.33% -68.77% -141.18%  
      operating margin %
    		                            
      other income:
    		                            
      interest expense
    		-62,814,000 -56,939,000 -61,662,000 -65,511,000 -65,719,000 -65,703,000  -50,857,000 -49,315,000 -47,028,000 -42,391,000 -35,623,000 -33,335,000 -33,957,000 -34,400,000 -34,083,000 -33,885,000 -34,535,000 -34,895,000 -36,669,000 -39,899,000 -38,829,000 -42,209,000 -43,886,000 -43,281,000 -42,880,000 -43,018,000 -36,622,000 
      foreign exchange gain
    		-3,431,000 4,247,000 -7,661,000 2,274,000 -262,000 -1,197,000  421,000 1,901,000    -2,013,000 -170,000 -29,000 -2,244,000 2,088,000 8,392,000 9,673,000 3,466,000    8,311,000 -5,464,000 2,817,000 -5,137,000 -25,946,000 
      decrease (increase) in tax receivable agreement liability
    		20,808,000                            
      loss on refinancing
    		-31,365,000         -72,750  -291,000                 
      other income
    		1,235,000 518,000 2,172,000 1,178,000 4,360,000 4,072,000  12,000 3,539,000 2,772,000 5,709,000 7,230,000 2,122,000 6,633,000 3,871,000 4,032,000 794,000 488,000 898,000 571,000 633,000 -237,000 446,000 149,000 1,107,000 2,123,000 -1,014,000 791,000 
      total other income
    		-75,567,000 -62,861,000 -91,112,000 -73,386,000 -75,065,000 -64,776,000  -50,424,000 -43,875,000 -43,687,000 -42,173,000 -34,113,000 -33,226,000 -27,494,000 -30,558,000 -32,295,000 -31,003,000 -25,655,000 -24,324,000 -32,509,000 -44,447,000 -33,976,000 138,550,000 -37,314,000 -38,820,000 -38,086,000 -51,981,000 -81,444,000 
      income before income taxes
    		-5,223,000 37,486,000 -15,319,000 15,423,000 20,405,000 -75,522,000  29,660,000 -9,426,000 -7,655,000 2,180,000 -232,731,000 -9,921,000 -16,319,000 -2,043,000 34,824,000 14,904,000 -5,477,000 -21,889,000 -21,758,000 13,344,000 -57,111,000 26,276,000 -56,227,000 -133,180,000 -14,806,000 22,574,000 -262,506,000 
      (benefit from) benefit from income taxes
    		-23,355,000       -23,000     -3,461,000            -8,428,000   -12,416,000 
      net income
    		18,132,000 24,618,000 -20,742,000 11,757,000 16,787,000 -81,678,000  29,683,000 -10,094,000 -5,858,000 -2,390,000 -240,081,000 -6,460,000 -20,459,000 -6,092,000 32,176,000 14,545,000 -6,962,000 -22,033,000 -23,944,000 121,517,000 -64,903,000 -363,392,000 -50,526,000 -124,752,000 -20,330,000 17,465,000 -250,090,000 
      yoy
    		8.01% -130.14%  -60.39% -266.31% 1294.30%  -112.36% 56.25% -71.37% -60.77% -846.15% -144.41% 193.87% -72.35% -234.38% -88.03% -89.27% -93.94% -52.61% -197.41% 219.25% -2180.69% -79.80%     
      qoq
    		-26.35% -218.69% -276.42% -29.96% -120.55%   -394.07% 72.31% 145.10% -99.00% 3616.42% -68.42% 235.83% -118.93% 121.22% -308.92% -68.40% -7.98% -119.70% -287.23% -82.14% 619.22% -59.50% 513.64% -216.40% -106.98%  
      net income margin %
    		                            
      less: net income attributable to non-controlling interests
    		-15,763,000 -12,423,000 -8,167,750 -11,913,000 -10,793,000    3,151,000        -7,839,000 3,925,000 13,058,000 11,948,000    33,624,000     
      net income attributable to amneal pharmaceuticals, inc.
    		2,369,000 12,195,000 -31,081,000 -156,000 5,994,000 -91,643,000  11,917,000 -6,943,000 -4,333,000 -2,689,000 -120,808,000 -2,156,000 -6,377,000 -4,237,000 14,532,000 6,706,000 -3,037,000 -8,975,000 -11,996,000 115,067,000 -32,128,000 -265,006,000 -16,902,000 -47,881,000 -8,768,000 6,952,000 -19,104,000 
      net income per share
    		                            
      basic
    		0.01 0.04 -0.07  0.02   0.08  -0.03 -0.02 -0.8 -0.01 0.028 -0.03 0.1 0.05            
      diluted
    		0.01 0.04 -0.07  0.02   0.08  -0.03 -0.02 -0.8 -0.01 0.028 -0.03 0.1 0.04            
      weighted-average common shares outstanding:
    		                            
      basic
    		314,168 311,054  309,647 309,117  176,136 153,738  150,944 151,393 150,993 149,892  149,290 148,996 148,013            
      diluted
    		324,754 323,961  309,647 318,957  176,136 154,887  150,944 151,393 150,993 149,892  149,290 151,986 151,220            
      charges related to legal matters
    		    699,000   2,017,000  20,094,000 285,000 251,877,000  6,000,000 19,000,000   1,465,000 60,000 1,300,000 4,500,000        
      increase in tax receivable agreement liability
    		 -10,687,000 -23,961,000 -11,327,000 -13,444,000 -1,948,000                       
      benefit from income taxes
    		 12,868,000 5,423,000 3,666,000 3,618,000 6,156,000   668,000 -1,797,000 4,570,000 7,350,000  4,140,000 4,049,000 2,648,000 359,000 -26,460,750 144,000 2,186,000 -108,173,000 7,792,000 389,668,000 -5,701,000  -1,735,750 5,109,000  
      change in fair value of contingent consideration
    		   -1,030,000  100,000  -6,364,000 2,457,000 2,226,000 -1,425,000 -270,000 200,000 -100,000 300,000              
      charges (credit) related to legal matters
    		     94,359,000                       
      less: net (income) loss attributable to non-controlling interests
    		     -9,965,000  -17,766,000  30,929,000 -299,000     -17,644,000     -6,450,000     5,297,750 -10,577,000  
      net income per share
    		                            
      basic and diluted
    		     -0.3   -0.05                    
      weighted-average common shares outstanding:
    		                            
      basic and diluted
    		  308,978   307,279   152,109                    
      acquisition, transaction-related and integration expenses
    		         -5,000 39,000 241,000 434,000 836,000 134,000 4,283,000 2,802,000 3,585,000 1,041,000 1,787,000 2,575,000 3,706,000 3,131,000 3,519,000 6,032,000 4,945,000 2,231,000 207,507,000 
      insurance recoveries for property losses and associated expenses
    		           -1,911,000                 
      net income attributable to amneal pharmaceuticals, inc. before accretion of redeemable non-controlling interest
    		       11,917,000 -6,943,000 -4,333,000 -2,689,000 -120,808,000 -1,718,000         -32,128,000 -265,006,000 -16,902,000  -8,768,000 6,888,000 -17,864,000 
      accretion of redeemable non-controlling interest
    		            -438,000              64,000 -1,240,000 
      credit related to legal matters
    		        -436,000    -2,326,000                
      cost of goods sold impairment charges
    		         5,325,000 674,000 5,112,000  22,004,000 688,000    32,364,000 759,000 1,456,000 13,721,000 56,132,000 3,012,000 53,297,000    
      in-process research and development impairment charges
    		               710,000  1,720,000   960,000 450,000 23,382,000  22,787,000    
      charges (insurance recoveries) for property losses and associated expenses
    		         -477,750                   
      foreign exchange loss
    		         -3,233,250 -5,491,000 -5,429,000         -5,181,000 -2,421,000 -12,531,000      
      less: net income (income) attributable to non-controlling interests
    		           119,273,000 4,742,000 -5,907,000 1,855,000       32,775,000 98,386,000  76,871,000   31,885,000 
      property losses and associated expenses
    		             -2,818,000 8,186,000              
      gain on sale of international businesses
    		                   123,000  328,000  -1,888,000     
      gain from reduction of tax receivable agreement liability
    		                     40,000 192,844,000      
      net income per share
    		                            
      class a and class b-1 basic
    		                 -0.02 -0.06 -0.08 0.78 -0.64 -2.03   -0.025 0.05  
      class a and class b-1 diluted
    		                 -0.02 -0.06 -0.08 0.78 -0.64 -2.03   -0.025 0.05  
      weighted-average common shares outstanding:
    		                            
      gain on sale of international business
    		                        8,818,000    
      charges (gains) related to legal matters
    		                     -2,308,000 14,750,000      
      loss on extinguishment of debt
    		                           -19,667,000 
      less: net income attributable to amneal pharmaceuticals llc pre- combination
    		                            
      legal settlement gains
    		                            
      less: net income attributable to amneal pharmaceuticals llc pre-combination
    		                            
      class a and class b-1 basic and diluted
    		                       -0.13 -0.37   -0.15 
      legal settlement gain
    		                            
      restructuring (benefit) expenses
    		                         10,577,250 -2,156,000  
      loss on sale of certain international businesses
    		                         -146,000 -2,812,000  
      less: net (income) loss attributable to amneal pharmaceuticals llc pre-combination
    		                         37,201,500   
      restructuring expenses
    		                           44,465,000 
      less: net income (income) attributable to amneal pharmaceuticals llc pre-combination
    		                           200,341,000 
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.